keyword
MENU ▼
Read by QxMD icon Read
search

Detemir

keyword
https://www.readbyqxmd.com/read/28105735/observational-registry-of-basal-insulin-treatment-orbit-in-patients-with-type-2-diabetes-uncontrolled-with-oral-antihyperglycaemic-drugs-real-life-use-of-basal-insulin-in-china
#1
Linong Ji, Puhong Zhang, Dongshan Zhu, Xian Li, Jiachao Ji, Juming Lu, Xiaohui Guo, Weiping Jia, Jianping Weng, Yangfeng Wu, Wenying Yang, Dajin Zou, Zhiguang Zhou, Changyu Pan, Yan Gao, Satish K Garg
AIMS: To examine treatment patterns following basal insulin (BI) introduction in type 2 diabetes mellitus (T2DM) patients under real-world conditions across China. MATERIALS AND METHODS: Overall, 18,995 patients inadequately controlled [HbA1c ≥ 53 mmol/mol (7%)] with oral antihyperglycaemic drugs (OADs) and willing to receive BI treatment were registered at 209 hospitals and followed at baseline (visit 1), 3 months (visit 2), and 6 months (visit 3). Type of BI was initiated at physicians' discretion...
January 20, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28100192/design-and-rationale-of-a-large-international-prospective-cohort-study-to-evaluate-the-occurrence-of-malformations-and-perinatal-neonatal-death-using-insulin-detemir-in-pregnant-women-with-diabetes-in-comparison-with-other-long-acting-insulins
#2
Elisabeth R Mathiesen, Henning Andersen, Sofia I I Kring, Peter Damm
BACKGROUND: There are a lack of data regarding the effect of basal insulin analogues on rates of events like congenital malformation and perinatal mortality in diabetic pregnancy. METHODS: The present study is a prospective, non-interventional, multicentre cohort study conducted in seven countries, designed to assess the safety of insulin detemir during pregnancy, and to monitor the health status of resulting infants (exposed in utero) up to 1 year of age. The study population includes women with type 1 or type 2 diabetes, who are pregnant and being treated with insulin...
January 18, 2017: BMC Pregnancy and Childbirth
https://www.readbyqxmd.com/read/28099755/comparing-effects-of-insulin-analogues-and-human-insulin-on-nocturnal-glycaemia-in-hypoglycaemia-prone-people-with-type-1-diabetes
#3
P L Kristensen, L Tarnow, C Bay, K Nørgaard, T Jensen, H-H Parving, H Perrild, H Beck-Nielsen, J S Christiansen, B Thorsteinsson, U Pedersen-Bjergaard
AIMS: To assess the difference between analogue and human insulin with regard to nocturnal glucose profiles and risk of hypoglycaemia in people with recurrent severe hypoglycaemia. METHODS: A total of 72 people [46 men, mean ± sd age 54 ± 12 years, mean ± sd HbA1c 65 ± 12 mmol/mol (8.1 ± 1.1%), mean ± sd duration of diabetes 30 ± 14 years], who participated in a 2-year randomized, crossover trial of basal-bolus therapy with insulin detemir/insulin aspart or human NPH insulin/human regular insulin (the HypoAna trial) were studied for 2 nights during each treatment...
January 18, 2017: Diabetic Medicine: a Journal of the British Diabetic Association
https://www.readbyqxmd.com/read/28061430/exploring-the-characteristics-of-suboptimally-controlled-patients-after-24weeks-of-basal-insulin-treatment-an-individualized-approach-to-intensification
#4
Kamlesh Khunti, Taner Damci, Lise Lotte Husemoen, Vinay Babu, Andreas Liebl
AIM: To identify characteristics of suboptimally controlled patients with type 2 diabetes (T2DM) on basal insulin treatment who may benefit from intensive titration or further intensification of treatment. METHODS: A post hoc analysis of SOLVE: a 24-week, international, observational study conducted in 17,374 patients with T2DM inadequately controlled on oral antidiabetic drugs (OADs) started on once-daily insulin detemir. Patients were divided into two groups based on whether they achieved HbA1c<7...
December 9, 2016: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/28042719/insulins-nph-glargine-and-detemir-and-risk-of-severe-hypoglycaemia-among-working-age-adults
#5
Arto Y Strandberg, Houssem Khanfir, Sari Mäkimattila, Tero Saukkonen, Timo E Strandberg, Fabian Hoti
INTRODUCTION: The longer acting basal insulin analogues glargine and detemir have shown a lower incidence of hypoglycaemia compared to insulin NPH in clinical studies. We evaluated the real-life risk of severe hypoglycaemia among new users of insulins in the working-age population in Finland. METHODS: All persons aged 18-65 years with diabetes mellitus who were newly prescribed with insulins NPH, glargine, or detemir during 2006-2009, were identified from national registers...
December 31, 2016: Annals of Medicine
https://www.readbyqxmd.com/read/28012403/the-potential-for-improvement-of-outcomes-by-personalized-insulin-treatment-of-type-1-diabetes-as-assessed-by-analysis-of-single-patient-data-from-a-randomized-controlled-cross-over-insulin-trial
#6
Ulrik Pedersen-Bjergaard, Peter L Kristensen, Henning Beck-Nielsen, Kirsten Nørgaard, Hans Perrild, Jens S Christiansen, Tonny Jensen, Hans-Henrik Parving, Birger Thorsteinsson, Lise Tarnow
AIMS: The evidence for optimal insulin treatment in type 1 diabetes is mainly based on randomised controlled trials applying a parallel-group design. Such trials yield robust general results but crucial individual treatment effects cannot be extracted. We aimed to assess the potential for further improvement of outcomes by personalized insulin therapy by analyzing data from a cross-over trial at individual level. METHODS: Post hoc analysis of data from a two-year multicentre, prospective, randomised, open, blinded endpoint (PROBE) trial (the HypoAna trial)...
November 16, 2016: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/27914019/erratum-to-hydrophobic-interaction-between-domain-i-of-albumin-and-b-chain-of-detemir-may-support-myristate-dependent-detemir-albumin-binding
#7
Sadaf Fatima, Priyankar Sen, P Sneha, C George Priyadoss
No abstract text is available yet for this article.
December 2, 2016: Applied Biochemistry and Biotechnology
https://www.readbyqxmd.com/read/27854036/hydrophobic-interaction-between-domain-i-of-albumin-and-b-chain-of-detemir-may-support-myristate-dependent-detemir-albumin-binding
#8
Sadaf Fatima, Priyankar Sen, P Sneha, C George Priyadoss
The bindings of detemir [LysB29(Nε-tetradecanoyl)des(B30)-insulin] with two highly homologous albumins, HSA (human serum albumin) and BSA (bovine serum albumin), were investigated through CD, spectrofluorophotometry, and molecular docking analysis. The absence of any tryptophanyl residue in detemir makes albumin binding study possible by exclusive tryptophanyl spectral quenching at 340 nm (λem = 296 nm). The interactions found to be static (Kq > 10(10) M(-1) s(-1)) with Stern-Volmer constants ≈10(3) M(-1)...
November 16, 2016: Applied Biochemistry and Biotechnology
https://www.readbyqxmd.com/read/27819164/current-trends-in-the-diagnosis-and-management-of-gestational-diabetes-mellitus-in-the-united-states
#9
Brianne E Bimson, Barak M Rosenn, Sara A Morris, Elizabeth B Sasso, Rachelle A Schwartz, Lois E Brustman
OBJECTIVE: To assess current practice patterns among members of the Society for Maternal-Fetal Medicine (SMFM) with respect to the diagnosis and management of gestational diabetes mellitus (GDM). METHODS: A 38 question survey on GDM diagnosis and management was distributed to SMFM members. RESULTS: 2330 SMFM members were surveyed with a 40% response rate. Overall, 90.6% of respondents recommend a 2-step (versus a 1-step) diagnostic test. Cutoff values for the 1-h-50 g glucose challenge test vary from 130-140 mg/dL, but the majority (83%) adopts Carpenter Coustan criteria for the 3-h-100 g oral glucose tolerance test...
November 24, 2016: Journal of Maternal-fetal & Neonatal Medicine
https://www.readbyqxmd.com/read/27737571/hypoglycemia-in-patients-with-type-2-diabetes-newly-initiated-on-basal-insulin-in-the-us-in-a-community-setting-impact-on-treatment-discontinuation-and-hospitalization
#10
Mehul R Dalal, Mahmood R Kazemi, Fen Ye
OBJECTIVE: To evaluate the impact of 6 month hypoglycemia on treatment discontinuation and hospitalization of patients initiating basal insulin for type 2 diabetes (T2D) in real-world practice. METHODS: This was a retrospective cohort study of patient-level data using electronic medical records (EMRs) in the Predictive Health Intelligence diabetes dataset. Data from adult patients with T2D initiating basal insulin glargine, insulin detemir, or Neutral Protamine Hagedorn insulin between January 2008 and March 2014 was analyzed...
February 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27618501/switching-from-twice-daily-glargine-or-detemir-to-once-daily-degludec-improves-glucose-control-in-type-1-diabetes-an-observational-study
#11
S Galasso, A Facchinetti, B M Bonora, V Mariano, F Boscari, E Cipponeri, A Maran, A Avogaro, G P Fadini, D Bruttomesso
BACKGROUND AND AIMS: Degludec is an ultralong-acting insulin analogue with a flat and reproducible pharmacodynamic profile. As some patients with type 1 diabetes (T1D) fail to achieve 24-h coverage with glargine or detemir despite twice-daily injections, we studied the effect of switching T1D patients from twice-daily glargine or detemir to degludec. METHODS AND RESULTS: In this prospective observational study, T1D patients on twice-daily glargine or detemir were enrolled...
December 2016: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://www.readbyqxmd.com/read/27610430/allergic-reactions-to-insulin-detemir-in-women-with-gestational-diabetes-mellitus
#12
Adam Morton, Josephine Laurie
No abstract text is available yet for this article.
July 2016: Australian Family Physician
https://www.readbyqxmd.com/read/27600385/development-of-insulin-detemir-insulin-aspart-cross-reacting-antibodies-following-treatment-with-insulin-detemir-104-week-study-in-children-and-adolescents-with-type-1-diabetes-aged-2-16%C3%A2-years
#13
Nandu Thalange, Abdullah Bereket, Lisbeth Bjerring Jensen, Line Conradsen Hiort, Valentina Peterkova
BACKGROUND: To study the long-term development (104 weeks) of insulin antibodies during treatment with insulin detemir (IDet) and insulin aspart (IAsp) in children with type 1 diabetes aged 2-16 years. METHODS: A 52-week, two-arm, randomized trial comparing IDet and neutral protamine Hagedorn insulin, both in combination with IAsp, was followed by a one-arm, 52-week extension trial of the IDet + IAsp arm. The present analysis was conducted in children who completed the randomized trial and entered into the extension trial...
December 2016: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/27597308/insulin-detemir-versus-glyburide-in-women-with-gestational-diabetes-mellitus
#14
Ronit Koren, Eran Ashwal, Moshe Hod, Yoel Toledano
AIM: To evaluate the safety, efficacy and pregnancy outcomes of insulin detemir (IDet) versus glyburide treatment in women with gestational diabetes mellitus (GDM). METHODS: We conducted a retrospective cohort study of women with GDM who were treated with either glyburide or IDet for GDM in a university-affiliated tertiary hospital. RESULTS: Ninety-one patients with GDM were enrolled, 62 were administered glyburide and 29 IDet. Maternal age, pregestational body mass index (BMI) and rate of abnormal oral glucose tolerance test (OGTT) blood glucose values were not significantly different between groups...
November 2016: Gynecological Endocrinology
https://www.readbyqxmd.com/read/27593206/impact-of-the-mode-of-protraction-of-basal-insulin-therapies-on-their-pharmacokinetic-and-pharmacodynamic-properties-and-resulting-clinical-outcomes
#15
REVIEW
Tim Heise, Chantal Mathieu
Manufacturers of insulin products for diabetes therapy have long sought ways to modify the absorption rate of exogenously administered insulins in an effort to better reproduce the naturally occurring pharmacokinetics of endogenous insulin secretion. Several mechanisms of protraction have been used in pursuit of a basal insulin, for which a low injection frequency would provide tolerable and reproducible glucose control; these mechanisms have met with varying degrees of success. Before the advent of recombinant DNA technology, development focused on modifications to the formulation that increased insulin self-association, such as supplementation with zinc or the development of preformed precipitates using protamine...
January 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27589235/sustained-treatment-with-insulin-detemir-in-mice-alters-brain-activity-and-locomotion
#16
Tina Sartorius, Anita M Hennige, Andreas Fritsche, Hans-Ulrich Häring
AIMS: Recent studies have identified unique brain effects of insulin detemir (Levemir®). Due to its pharmacologic properties, insulin detemir may reach higher concentrations in the brain than regular insulin. This might explain the observed increased brain stimulation after acute insulin detemir application but it remained unclear whether chronic insulin detemir treatment causes alterations in brain activity as a consequence of overstimulation. METHODS: In mice, we examined insulin detemir's prolonged brain exposure by continuous subcutaneous (s...
2016: PloS One
https://www.readbyqxmd.com/read/27547422/predictors-of-sustained-drug-free-diabetes-remission-over-48%C3%A2-weeks-following-short-term-intensive-insulin-therapy-in-early-type-2-diabetes
#17
Caroline K Kramer, Bernard Zinman, Haysook Choi, Ravi Retnakaran
OBJECTIVE: In early type 2 diabetes (T2DM), short-term intensive insulin therapy (IIT) for 2-4 weeks can decrease insulin resistance, reduce glucagonemia, improve β-cell function, and even induce a remission of diabetes that can last up to 1 year in some patients. However, little is known about the predictors of such a sustained remission. METHODS: We evaluated data from the placebo arm of a double-blind randomized controlled trial in which patients with early T2DM (≤7 years duration) underwent 4 weeks of IIT (basal detemir, bolus aspart), followed by placebo therapy for 48 weeks (n=25)...
2016: BMJ Open Diabetes Research & Care
https://www.readbyqxmd.com/read/27462470/ten-year-trends-in-the-morbidity-of-diabetes-mellitus-and-antidiabetic-drug-utilization-in-croatia-a-study-based-on-routinely-collected-data
#18
Renata Pavlov, Ivančica Topličan, Mladenka Vrcić Keglević
Objectives. To investigate trends of diabetes mellitus (DM) morbidity and antidiabetic drug utilization in Croatian primary health care (PHC) from 2005 to 2014. Method. Routinely collected morbidity data from all PHC units, presented in Croatian health-statistics yearbooks, were retrieved. Data on drug utilization were retrieved from the Annual Reports of the Croatian Agency for Medicinal Products and Medical Devices (ATC/DDD, antidiabetic, A10). Results. Total morbidity increased by 33.3% and DM increased by 65...
2016: International Journal of Family Medicine
https://www.readbyqxmd.com/read/27441092/flying-under-the-radar-treatment-of-refractory-hyperglycemia
#19
S M Kandel, J A Cosgriff
UNLABELLED: Clinicians are often presented with the scenario of what to do when one medication in a drug class has failed a therapeutic trial on a patient. We encountered a patient who developed profound resistance to glargine, aspart and regular insulin, but had a rapid and sustained response to detemir. The mechanism of the increased sensitivity to detemir is unclear, but may be related to an additional carbon chain on detemir shielding it from an antibody response. This case highlights the profound impact that subtle differences in molecular structure can have on biological activity and thus patient outcomes...
2016: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/27366709/clinical-safety-of-insulin-detemir-in-patients-with-type-2-diabetes-in-the-gulf-countries-the-multicenter-noninterventional-open-label-levsafe-study
#20
Abdel Rahman El Shiekh, Hesham A Farrag, Tarek Ashour, Khalid Zaki Alshali, Waleed AbdelFattah
AIM: To evaluate the safety profile of insulin detemir (IDet) in people with Type 2 diabetes mellitus (T2DM) in the Gulf countries in the 32-week, noninterventional LevSafe study. METHODS: People with T2DM whose physicians had opted to start IDet therapy were included in the study. Safety parameters, including serious adverse drug reactions (SADRs) and hypoglycemia, and changes in body weight and glycemic control were evaluated at baseline, week 16 and week 32. RESULTS: A total of 686 patients were exposed to IDet therapy with a mean (±standard deviation) age, body mass index, and diabetes duration of 51...
July 2016: Indian Journal of Endocrinology and Metabolism
keyword
keyword
42764
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"